Switching Patterns Among Diabetic Macular Edema: Regeneron’s Eylea Withstands the Evolving DME Switch Landscape
With the DME treatment landscape evolving, ophthalmologists have the opportunity to explore more novel approaches in hopes of easing treatment burden. But will they take the plunge and stray from the tried-and-true options? EXTON, Pa., February 13, 2023 – The patient switch territory is evolving as more agents become available. Spherix’s RealWorld Dynamix™ report allows […]
Ardelyx’s Tenapanor (IBSRELA) Becomes a Relevant Player in the Irritable Bowel Syndrome with Constipation Market as the Company Awaits Important Regulatory News for the Drug in Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Surveyed nephrologists indicate enormous unmet need for new drugs to treat hyperphosphatemia and anticipate early adoption if the product is approved by the FDA EXTON, Pa., December 14, 2022 – After receiving an unexpected Complete Response Letter (CRL) from the FDA in July 2021 for tenapanor (marketed as XPHOZAH) to treat hyperphosphatemia, Ardelyx pivoted and […]
Spherix Global Insights Announces Special Coverage of Amgen’s Amjevita Launch, Tracking Uptake and Perceptions of the First Commercially-available Biosimilar to AbbVie’s Humira
According to a survey of autoimmune specialists, in the first week of launch, aided awareness of Amjevita is high, but willingness to prescribe is lacking. EXTON, Pa., February 6, 2023 – AbbVie’s Humira (adalimumab) is the world’s best selling drug, but the entry of biosimilar challengers, with Amgen’s Amjevita being the first of many more […]
Substantial Changes in Management of Patients with Chronic Kidney Disease as New Treatment Options Such as Bayer’s Kerendia and SGLT2 Inhibitors Gain Traction in US and EU Markets
Spherix Global Insights announces insights pulled from chart audit data from thousands of patients highlighting the evolution of chronic kidney disease (CKD) patient care EXTON, Pa. /January 20, 2023/PRNewswire/ – With SGLT2 inhibitors increasingly becoming the standard of care for diabetic and non-diabetic CKD patients, the broader CKD treatment has begun to change notably. Feedback […]
Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech’s Vabysmo Rising, Regeneron’s Eylea and Genentech’s Off-Label Avastin Remain Strong, According to Spherix Global Insights
Despite the availability of new agents, established brands remain market leaders within the switch segment. EXTON, Pa., January 18, 2023/PR Newswire/ The switch landscape represents an active segment of the market where brands have the opportunity to capture share. Spherix’s RealWorld Dynamix™ service takes a unique approach to the typical collection of patient-level data, capturing […]
Implications of Biosimilar Availability in the United States’ Ophthalmology Markets Highlighted in New Spherix Global Insights Study
80 US ophthalmologists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment landscape EXTON, Pa., January 10, 2023 – Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung’s Byooviz and Coherus Bioscience’s Cimerli (both biosimilars to […]
